Intracerebral Implantation of Autologous Peripheral Blood Stem Cells in Stroke Patients: A Randomized Phase II Study
| العنوان: | Intracerebral Implantation of Autologous Peripheral Blood Stem Cells in Stroke Patients: A Randomized Phase II Study |
|---|---|
| المؤلفون: | Yi-Jui Liu, Wei Lee, Chau Chin Lee, Der-Cherng Chen, Chon-Haw Tsai, Chen Huan Lin, Chao-Chun Lin, Jia Rong Fan, Woei Cherng Shyu, Der Yan Cho, Shinn Zong Lin, Jui-Cheng Chen |
| المصدر: | Cell Transplantation, Vol 23 (2014) |
| بيانات النشر: | SAGE Publishing, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Time Factors, Biomedical Engineering, Urology, CD34, Phases of clinical research, lcsh:Medicine, Peripheral Blood Stem Cells, Transplantation, Autologous, law.invention, Randomized controlled trial, law, medicine, Humans, Stroke, Aged, Demography, Transplantation, business.industry, Cerebral infarction, lcsh:R, Hematopoietic Stem Cell Transplantation, Cell Biology, Middle Aged, Evoked Potentials, Motor, Hematopoietic Stem Cells, medicine.disease, Clinical trial, Diffusion Tensor Imaging, Treatment Outcome, Female, business, Follow-Up Studies |
| الوصف: | In our previous study, intracerebral implantation of peripheral blood stem cells (PBSCs) improved functional outcome in rats with chronic cerebral infarction. Based on this finding, a randomized, single blind controlled study was conducted in 30 patients [PBSC group ( n = 15) and control group ( n = 15)] with middle cerebral artery infarction confirmed on a T2-weighted MRI 6 months to 5 years after a stroke. Only subjects with neurological deficits of intermediate severity based on the National Institute of Health Stroke Scale (NIHSS; range: 9–20) that had been stable for at least 3 months were enrolled. Those in the PBSC group received subcutaneous G-CSF injections (15 μg/kg/day) for 5 consecutive days, and then stereotaxic implantation of 3–8 × 106 CD34+ immunosorted PBSCs. All 30 patients completed the 12-month follow-up. No serious adverse events were noted during study period. Improvements in stroke scales (NIHSS, ESS, and EMS) and functional outcomes (mRS) from baseline to the end of the 12-month follow-up period were significantly greater in the PBSC than the control group. The fiber numbers asymmetry (FNA) scores based on diffusion tensor image (DTI) tractography were reduced in every PBSC-treated subject, but not in the control group. Reduction in the FNA scores correlated well with the improvement in NIHSS. Furthermore, a positive motor-evoked potential (MEP) response by transcranial magnetic stimulation (TMS) appeared in 9 of the 15 subjects in the PBSC group. This phase II study demonstrated that implantation of autologous CD34+ PBSC was safe, feasible, and effective in improving functional outcome. |
| اللغة: | English |
| تدمد: | 1555-3892 0963-6897 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38bfa3e40800a99b92cdf2b9ab5fb242 https://doaj.org/article/82d0fd096a18459b974414a897f624ba |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....38bfa3e40800a99b92cdf2b9ab5fb242 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15553892 09636897 |
|---|